Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC
November 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More